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Abstract Since the identification of phosphorylated and
truncated transactive response DNA-binding protein 43
(TDP-43) as a primary component of ubiquitinated inclusions
in amyotrophic lateral sclerosis and frontotemporal lobar
degeneration with ubiquitin-positive inclusions, much effort
has been directed towards ascertaining how TDP-43 contrib-
utes to the pathogenesis of disease. As with other protein
misfolding disorders, TDP-43-mediated neuronal death is
l i k e l yc a u s e db yb o t hat o x i cg a i na n dl o s so fT D P - 4 3
function. Indeed, the presence of cytoplasmic TDP-43
inclusions is associated with loss of nuclear TDP-43. More-
over, post-translational modifications of TDP-43, including
phosphorylation, ubiquitination, and cleavage into C-terminal
fragments, may bestow toxic properties upon TDP-43 and
cause TDP-43 dysfunction. However, the exact neurotoxic
TDP-43 species remain unclear, as do the mechanism(s) by
which they cause neurotoxicity. Additionally, given our
incomplete understanding of the roles of TDP-43, both in the
nucleus and the cytoplasm, it is difficult to truly appreciate the
detrimental consequences of aberrant TDP-43 function. The
development of TDP-43 transgenic animal models is expected
to narrow these gaps in our knowledge. The aim of this review
is to highlight the key findings emerging from TDP-43
transgenic animal models and the insight they provide into
the mechanisms driving TDP-43-mediated neurodegeneration.
Keywords TDP-43.Neurodegeneration.Amyotrophic
lateral sclerosis.Frontotemporal lobar degeneration.
Transgenic animal models
Introduction
Many neurodegenerative diseases are characterized by the
misfolding and aggregation of proteins into intracellular
inclusions. The transactive response DNA-binding protein
43 (TDP-43) was recognized as one such protein when, in
2006, it was identified as a primary component of
ubiquitinated inclusions in the most frequent form of
frontotemporal lobar degeneration (FTLD) and in most
cases of amyotrophic lateral sclerosis (ALS; Arai et al.
2006; Neumann et al. 2006).
Frontotemporal dementia (FTD), the third most common
cause of dementia in industrialized countries after Alz-
heimer’s disease (AD) and dementia with Lewy bodies
(Neary et al. 1998; Snowden et al. 2002), encompasses a
heterogeneous group of neurodegenerative disorders distin-
guished clinically by abnormalities in behavior, language,
and personality (Seelaar et al. 2011). The most common
clinical syndrome, behavioral-variant FTD, is associated
with disinhibition and social inappropriateness. Other
clinical syndromes include progressive non-fluent aphasia
and semantic dementia. In some instances, FTD patients
display movement abnormalities with clinical features of
motor neuron disease (MND) resembling ALS. FTLD is the
neuropathologic substrate of FTD being characterized by
the predominant atrophy of the frontal and temporal lobes
and the presence of proteinaceous inclusions in neurons and
glia. It is broadly divided into cases with tau-positive
inclusions (FTLD-tau) and those with tau-negative,
ubiquitin-positive inclusions (FTLD-U). The ubiquitinated
protein in most FTLD-U cases is TDP-43, and these are
consequently classified as FTLD–TDP.
ALS is characterized by the progressive degeneration of
motor neurons in the cerebral cortex (upper motor neurons),
brain stem, and spinal cord (lower motor neurons), resulting
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ALS can involve several non-motor systems and subcorti-
cal structures, and there is evidence of cognitive deficits in
a considerable number of ALS patients (Lowe 1994; Abe et
al. 1997; Frank et al. 1997; Lomen-Hoerth et al. 2003;
Ringholz et al. 2005; Murphy et al. 2007). Cytoplasmic
ubiquitin-positive inclusions are present in lower motor
neurons and, less frequently, upper motor neurons (Leigh et
al. 1991; Ince et al. 1998). In cases of ALS with dementia,
and in some patients with minor cognitive changes,
ubiquitin-positive inclusions are also present in other brain
regions including the extramotor neocortex and hippocampus
(Okamoto et al. 1991; Wightman et al. 1992; Mackenzie and
Feldman 2005; Geser et al. 2008a). It is now well established
that TDP-43 is the primary component in glial and neuronal
inclusions present in most ALS patients, with the exception
of those with familial ALS caused by mutations in Cu/Zn
superoxide dismutase (SOD1) (Arai et al. 2006; Neumann et
al. 2006;C a i r n se ta l .2007; Davidson et al. 2007;G r o s s m a n
et al. 2007; Higashi et al. 2007a; Mackenzie et al. 2007;
Neumann et al. 2007; Seelaar et al. 2007; Tan et al. 2007;
Hatanpaa et al. 2008; Pikkarainen et al. 2008; Josephs et al.
2009). Based on the significant overlap of clinical and
pathological features among FTLD-TDP with or without
MND and ALS-TDP with or without dementia, it has
been suggested that these TDP-43 proteinopathies are
situated at points along one continuous clinicopatholog-
ical spectrum of multi-system neurodegenerative dis-
eases (Geser et al. 2010).
In addition to ALS-TDP and FTLD-TDP, TDP-43 pathol-
ogy has been observed, to a variable extent, in other
neurodegenerative disorders including Lewy body disease
(Higashi et al. 2007b; Nakashima-Yasuda et al. 2007),
parkinsonism–dementia complex of Guam (Hasegawa et al.
2007; Geser et al. 2008b), corticobasal degeneration (Arai et
al. 2006;U r y ue ta l .2008), Pick’s disease (Arai et al. 2006),
AD (Arai et al. 2006;A m a d o r - O r t i ze ta l .2007;H i g a s h ie t
al. 2007b;U r y ue ta l .2008), Perry syndrome (Wider et al.
2009), and hippocampal sclerosis (Amador-Ortiz et al. 2007;
Cairns et al. 2007). Whether the presence of TDP-43
pathology in these diseases indicates that TDP-43 contributes
to their development or progression has yet to be determined.
It is interesting to note, however, that the presence of TDP-
43 pathology in AD is associated with greater brain atrophy
and more severe clinical deficits (Josephs et al. 2008).
Studies also suggest that amyloid-β triggers TDP-43
pathology (i.e., TDP-43 phosphorylation, cleavage, and
accumulation in the cytosol) in mouse models of AD
(Caccamo et al. 2010; Herman et al. 2011), while TDP-43
overexpression heightens α-synuclein toxicity to dopaminer-
gic neurons in transgenic mice (Tian et al. 2011).
The identification of numerous missense mutations in
TARDBP, the gene encoding TDP-43, in sporadic and
familial ALS, as well as in patients with FTD, provides
evidence of a direct link between TDP-43 abnormalities
and neurodegeneration (Gitcho et al. 2008; Kabashi et al.
2008; Kuhnlein et al. 2008; Rutherford et al. 2008;
Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki
et al. 2008; Benajiba et al. 2009; Borroni et al. 2009;
Corrado et al. 2009; Daoud et al. 2009; Del Bo et al. 2009;
Gitcho et al. 2009; Kovacs et al. 2009; Lemmens et al.
2009). As with other protein misfolding diseases, TDP-43-
mediated neuronal death in ALS-TDP and FTLD-TDP is
likely caused by multiple pathways involving a combina-
tion of toxic gain and loss of TDP-43 function. The
sequestration of TDP-43 from the nucleus to cytoplasmic
inclusions is expected to result in loss of TDP-43 function.
The inclusions themselves may be neurotoxic, merely inert
by-products, or a protective mechanism used by cells to
sequester harmful TDP-43 species. Additionally, phosphor-
ylation, ubiquitination, and cleavage of TDP-43 into C-
terminal TDP-43 fragments, post-translational modifica-
tions observed only in disease, may both bestow toxic
properties upon TDP-43 and cause TDP-43 dysfunction.
As our knowledge of the normal function of TDP-43
continues to grow, so too shall our understanding of the
mechanisms that drive TDP-43-mediated neurodegenera-
tion. TDP-43, an RNA/DNA binding protein, is among the
class of heteregeneous riobonucleoproteins and is believed
to regulate multiple steps of RNA metabolism, including
transcription, splicing, mRNA transport, and microRNA
biosynthesis (Buratti and Baralle 2010). Although TDP-43
is largely a nuclear protein, it does shuttle between the
nucleus and cytoplasm in a transcription-dependent manner,
and a small proportion of TDP-43 is present in the
cytoplasm under physiological conditions (Ayala et al.
2008; Winton et al. 2008). This suggests that, in addition
to its nuclear functions, TDP-43 may play an important role
in the cytoplasm, a hypothesis that is strengthened by the
findings that the post-synaptic localization of TDP-43, in
the form of RNA granules, is enhanced following depolar-
ization of primary hippocampal neurons (Wang et al.
2008a) and that TDP-43 relocates to cytoplasmic stress
granules in response to harmful stimuli in cell and animal
models (Colombrita et al. 2009; Moisse et al. 2009a, b;
Freibaum et al. 2010; Liu-Yesucevitz et al. 2010; Dewey et
al. 2011; McDonald et al. 2011). Together, these findings
suggest that TDP-43 regulates synaptic plasticity by
controlling the transport and splicing of synaptic mRNAs
and assists in the physiological response to neuronal injury.
Recently developed rodent TDP-43 transgenic models
are expected to serve as valuable tools to better understand
the role of TDP-43 within the central nervous system, as
well as provide insight on the mechanisms by which TDP-
43 contributes to the development and progression of
neurodegeneration (Wegorzewska et al. 2009; Shan et al.
J Mol Neurosci (2011) 45:486–499 4872010; Stallings et al. 2010; Tsai et al. 2010; Wils et al.
2010; Xu et al. 2010; Zhou et al. 2010; Igaz et al. 2011;
Tian et al. 2011). The aim of this review is to highlight key
findings emerging from TDP-43 transgenic animals, as well
as some of the many questions in need of further
investigation.
Rodent Models of TDP-43 Overexpression
Several TDP-43 transgenic animal models have now been
generated (Table 1). Despite variations in the design of
these models, which include differences in the selection of
promoter driving transgene expression and, consequently,
the regional expression of exogenous TDP-43, in the form
of TDP-43 being expressed (i.e., mouse vs. human or wild-
type vs. mutant TDP-43), and even in the species chosen
for the model (mouse vs. rat), many commonalities exist
among them. For instance, ubiquitin accumulation, TDP-43
fragmentation, astrogliosis, microgliosis, axonal degenera-
tion, neuronal loss, motor function impairments, and
shortened lifespan are observed in many of the transgenic
animals (Table 1). Conspicuously lacking, however, is the
presence of overt TDP-43 cytoplasmic inclusions. Summa-
rized below are the findings that have emerged from the
primary characterization of the currently available TDP-43
transgenic mice and rats.
Behavioral Phenotypes in TDP-43 Transgenic Rodents
In four of the TDP-43 transgenic models discussed herein,
the TDP-43 transgene is under the control of the mouse
prion protein (PrP) promoter which drives high expression
in the brain and spinal cord, regions relevant to ALS.
Wegorzewska and colleagues (2009) generated a transgenic
mouse line that overexpresses flag-tagged human TDP-43
with the ALS-linked mutation, A315T. These mice develop
progressive gait abnormalities, weight loss, and finally
become unable to right or feed themselves by ∼5 months of
age. Notably, although transgene expression occurs
throughout the nervous system and other tissues, selective
toxicity is observed in layer V cortical neurons and in
spinal motor neurons (Wegorzewska et al. 2009). These
results indicate that PrP-TDP-43A315T mice develop motor
neuron disease with involvement of both cortical and spinal
motor neurons, reminiscent of human ALS.
Xu and colleagues (2010) observe a similar phenotype in
transgenic mice engineered to overexpress wild-type human
TDP-43. Homozygous PrP-TDP-43WT mice show reduced
body and brain weights, develop body tremors and gait
abnormalities, exhibit degenerating neurites, axons and
neurons in the spinal cord, and finally become unable to
right themselves between 1 and 2 months of age. Unlike
homozygous PrP-TDP-43WT mice, hemizygous mice are
virtually indistinguishable from non-transgenic controls,
indicating that TDP-43 expression must meet a certain
threshold for toxicity to ensue.
The findings generated from PrP-TDP-43A315T
(Wegorzewska et al. 2009) and PrP-TDP-43WT (Xu et al.
2010) mice indicate that both wild-type and mutant TDP-
43 overexpression is toxic. This is consistent with the
findings of Stallings and colleagues, who report that
founder mice expressing high levels of mutant TDP-43
(A315T or M337V) or wild-type TDP-43 develop early-
onset and progressive motor deficits, the severity of which
correlates with level of transgene expression in the spinal
cord. However, when comparing lines that express
intermediate levels of mutant or wild-type TDP-43, only
PrP-TDP-43A315T mice develop a progressive motor
phenotype and early lethality, with PrP-TDP-43WT mice
showing no obvious phenotype up to 11 months of age.
While these results suggest that mutant TDP-43 may be
more toxic than wild-type TDP-43, it must be kept in mind
that transgene expression in PrP-TDP-43WT mice is lower
than that in PrP-TDP-43A315T mice (Stallings et al. 2010).
Nonetheless, additional evidence of differential toxicity
between wild-type and mutant TDP-43 is provided by rat
transgenic models. The Xia group generated transgenic
rats that overexpress wild-type or mutant (M337V) human
TDP-43 utilizing a human TDP-43 “minigene” extracted
from a BAC clone. Founder miniTDP-43M337V rats
developed weakness, became paralyzed, and died at
postnatal ages. In contrast, miniTDP-43WT rats, which
expressed human wild-type TDP-43 protein at comparable
levels, did not develop paralysis by the age of 200 days,
suggesting that TDP-43M337V is indeed more toxic than
wild-type TDP-43 (Zhou et al. 2010). To overcome the
toxicity associated with the constitutive expression of
TDP-43M337V during development, rats conditionally
expressing TDP-43M337V were generated. iTDP-43M337V
expression in post-natal rats induces limb weakness and
paralysis, with axonal degeneration of motor neurons
occurring at disease onset. Progressive degeneration of
motor neurons and denervation atrophy of skeletal
muscles are subsequently observed. Moreover, neuro-
degeneration of cortical, hippocampal, and cerebellar
neurons occurs but at later time-points and less severely
than for motor neurons (Zhou et al. 2010). Using the CAG
promoter to drive robust and ubiquitous transgene expres-
sion, the Xia group next generated mice that overexpress
wild-type or mutant (M337V) human TDP-43 (Tian et al.
2011). Similar to their findings in rat, mice constitutively
expressing TDP-43M337V rapidly become immobile and
die soon after birth, thus preventing CAG-TDP-43M337V
lines from being established. In contrast, transgenic
founders overexpressing wild-type TDP-43 are healthy
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490 J Mol Neurosci (2011) 45:486–499and fertile. Other than a moderate loss of cortical neurons
at 10–12 months of age, homozygous CAG-TDP-43 mice
show no obvious abnormalities compared with non-
transgenic controls (Tian et al. 2011).
Transgenic mice that express wild-type TDP-43 under
control of the mouse Thy1 promoter, which drives expression
in post-natal neurons of the central nervous system, including
motor neurons, develop a similar phenotype as mice in which
transgene expression is regulated by the mouse PrP promoter
(Shan et al. 2010;W i l se ta l .2010). For instance, dose-
dependent degeneration of cortical and spinal motor neurons
is observed in the Thy1-TDP-43 mice generated by the
Kumar-Singh group. These mice develop abnormal hindlimb
reflex, reduced motor performance, and early lethality. Upon
comparing hemizygous and homozygous mice produced
from different founder lines, it was determined that human
TDP-43 expression dose-dependently influences the onset
and rate of disease progression (Wils et al. 2010). Similarly,
the severity of the phenotype observed in Thy1-TDP-43
mice developed by Shan and colleagues correlates with the
copy number of the transgene: mice with the highest
transgene copy number are markedly smaller than non-
transgenic littermates and die within 3 weeks of age, whereas
mice derived form lines expressing lower levels of transgene
exhibit less growth retardation and most live to adulthood.
Of note, transgenic males, which express human TDP-43 at
two- to threefold higher levels than transgenic females,
develop a more severe phenotype (Shan et al. 2010).
As in the above-mentioned models, transgenic mice in
which exogenous TDP-43 expression is controlled by the
Ca
2+/calmodulin-dependent kinase II (CaMKII) promoter,
which drives neuronal expression predominantly in the
forebrain but not in the spinal cord, develop progressive
motor deficits (Tsai et al. 2010). Tsai et al. (2010) observed
that their transgenic mice, which overexpress wild-type
mouse TDP-43 (mTDP-43), become impaired in motor
coordination, balance, and grip strength at 6 months of age.
CaMKII-mTDP-43 mice also develop abnormal limb-
clasping reflexes when suspended by their tails, a pheno-
type observed, albeit to a lesser extent, in iTDP-43 mice
that inducibly overexpress wild-type human TDP-43 under
the control of a CaMKII tetracycline transactivator (Igaz et
al. 2011). The motor deficits in these two models are likely
caused by the degeneration of upper motor neurons, which
express exogenous TDP-43 and not due to the degeneration
of lower motor neurons in the brainstem and spinal cord,
which do not express the transgene. Consistent with this, no
difference in the size and number of spinal cord motor
neurons is present in CaMKII-mTDP-43 mice, but a
reduction in the number of cortical neurons, as well as a
decrease in hippocampal volume, are observed (Tsai et al.
2010). In a similar fashion, iTDP-43 mice that conditionally
express high levels of human TDP-43, but not low-
expressing mice, show selective and progressive neuron
loss in the neocortex and hippocampal dentate gyrus (Igaz
et al. 2011). In addition to motor deficits, Tsai and
colleagues observe that their CaMKII-mTDP-43 mice
exhibit impaired learning and memory, as assessed by the
Morris water maze and fear-conditioning tasks. The
cognitive impairment in these transgenic mice is accompa-
nied by abnormalities in hippocampal long-term potentia-
tion, a form of synaptic plasticity believed to be required
for the molecular mechanisms of learning and memory. It is
worth noting that many TDP-43 RNA targets involved in
the long-term potentiation pathway are misregulated fol-
lowing depletion of TDP-43 from mouse adult brain
(Polymenidou et al. 2011).
Overall, axonal and/or neuronal degeneration, motor
deficits, and early lethality are relatively consistent features
among TDP-43 transgenic models. The mechanisms re-
sponsible for initiating these events, however, have yet to
be fully elucidated. Given that TDP-43 aggregation,
phosphorylation, and truncation are now considered hall-
mark features of ALS-TDP and FTLD-TDP, most groups
have investigated whether these abnormalities are present in
their transgenic models and whether they may contribute to
TDP-43-induced neurotoxicity.
TDP-43 Cytoplasmic Inclusions
Cytoplasmic ubiquitin- and TDP-43-immunopositive inclu-
sions are a defining feature in ALS-TDP and FTLD-TDP
(Arai et al. 2006; Neumann et al. 2006). An accumulation
of ubiquitin is observed in the nucleus and/or cytoplasm of
neurons of most TDP-43 transgenic rodent models, in the
form of multiple small aggregates, large aggregates, or
present diffusely (Wegorzewska et al. 2009; Shan et al.
2010; Stallings et al. 2010; Tsai et al. 2010; Wils et al.
2010; Xu et al. 2010; Zhou et al. 2010; Igaz et al. 2011). Of
interest, Wegorzewska and colleagues noted that the
cytoplasmic accumulation of ubiquitin, like neurodegen-
eration, occurs in cortical layer V and large neurons of
the ventral horn of the spinal cord in their Prp-TDP-
43A315T mice despite widespread transgene expression
(Wegorzewska et al. 2009). Similarly, although the Thy1
promoter drives wild-type human TDP-43 expression in
virtually all neurons of the brain, dense large neuronal
cytoplasmic and intranuclear inclusions composed of
ubiquitin are present only in cortical layer V of Thy1-
TDP-43 mice (Wils et al. 2010).
Immunoprecipitation studies have revealed that the
accumulation of ubiquitin observed in TDP-43 transgenic
models is not necessarily indicative of increased levels of
ubiquitinated TDP-43 per se; ubiquitinated TDP-43 is
detected in miniTDP-43M337V rats (Zhou et al. 2010), but
is not observed in PrP-TDP-43WT mice despite a marked
J Mol Neurosci (2011) 45:486–499 491increase in ubiquitin levels (Xu et al. 2010). Moreover,
while Tsai and colleagues do detect TDP-43-positive
cytoplasmic inclusions in ∼15–20% of cortical neurons of
their CaMKII-mTDP-43 mice, in most other models, TDP-
43-immunopositive cytoplasmic inclusions are seldom or
never observed when immunostaining of brain or spinal
cord sections is carried out using phosphorylation-
independent TDP-43 antibodies (Wegorzewska et al. 2009;
Shan et al. 2010; Stallings et al. 2010; Wils et al. 2010;X u
et al. 2010; Zhou et al. 2010; Igaz et al. 2011; Tian et al.
2011). Somewhat surprisingly, when using antibodies that
detect TDP-43 phosphorylated at S403/S404 or S409/S410,
sites abnormally phosphorylated in ALS-TDP and FTLD-
TDP (Hasegawa et al. 2008), TDP-43-positive intranuclear
inclusions, and punctate cytoplasmic inclusions are
detected, albeit with varying prevalence, in the spinal cord
and/or brain of many models (Wegorzewska et al. 2009;
Stallings et al. 2010; Wils et al. 2010; Xu et al. 2010; Zhou
et al. 2010; Igaz et al. 2011). It remains unclear why
phospho-TDP-43 antibodies are more sensitive at detecting
TDP-43 inclusions, but a similar effect is observed in
human tissue. For instance, a higher frequency of TDP-43
pathology is detected in AD patients when immunohisto-
chemistry is performed with phosphorylation-specific TDP-
43 antibodies (Arai et al. 2009) than with phosphorylation-
independent TDP-43 antibodies (Amador-Ortiz et al. 2007;
Uryu et al. 2008; Kadokura et al. 2009).
The general scarcity of TDP-43 cytoplasmic inclusions
within neurons of the currently available TDP-43 transgenic
animals argues against a primary role for such inclusions in
mediating the neurotoxic effects resulting from TDP-43
overexpression. Of course, while this indicates that TDP-43
inclusions are not required for neuronal death, it does not
exclude their pathogenic potential. Indeed, studies con-
ducted in yeast have shown that only those TDP-43 species
that form aggregates are toxic (Johnson et al. 2008).
Furthermore, ALS-linked mutations that accelerate aggre-
gation of human TDP-43 in vitro promote TDP-43 toxicity
in yeast (Johnson et al. 2009). Evidence that TDP-43
aggregation is detrimental to mammalian cells is provided
by a model in which a C-terminal TDP-43 fragment,
corresponding to a caspase cleavage product of TDP-43, is
overexpressed in differentiated human neuroblastoma cells
(Zhang et al. 2009). The aggregation of these fragments is
associated with increased cytotoxicity which likely results
from a toxic gain of function since it does not alter the
nuclear distribution of endogenous full-length TDP-43
(Zhang et al. 2009). Other studies, however, suggest that
it is the cytosolic localization of TDP-43 and not its
aggregation that causes neurotoxicity. While EGFP-TDP-
43A315Toverexpression in primary rat cortical neurons leads
to the formation of detergent-resistant inclusions, Barmada
and colleagues (2010) found that neuronal toxicity resulting
from EGFP-TDP-43A315T expression occurs independently
of inclusion formation. Rather, the amount of cytosolic
EGFP-TDP-43A315T was shown to be a powerful predictor
of cell death, suggesting that soluble forms of cytosolic
TDP-43 are neurotoxic (Barmada et al. 2010).
Cytoplasmic TDP-43 and C-Terminal TDP-43 Fragments
The diffuse redistribution of TDP-43 to the cytoplasm
appears to be an early event in ALS-TDP (Giordana et al.
2010). Despite the largely nuclear localization of exogenous
TDP-43 and the paucity of TDP-43 cytoplasmic inclusions
in TDP-43 transgenic rodents, diffuse cytoplasmic TDP-43
staining is occasionally observed (Stallings et al. 2010; Tsai
et al. 2010; Wils et al. 2010; Xu et al. 2010; Zhou et al.
2010). Additionally, C-terminal TDP-43 fragments are
present in many (Wegorzewska et al. 2009; Stallings et al.
2010; Tsai et al. 2010; Wils et al. 2010; Xu et al. 2010;
Zhou et al. 2010), but not all (Shan et al. 2010; Igaz et al.
2011), models. C-terminal TDP-43 fragments of ∼25 and
∼35 kDa are recovered in the sarkosyl-insoluble fraction of
affected brain regions of ALS-TDP and FTLD-TDP
patients (Neumann et al. 2006), and it is suspected that
they seed the aggregation of TDP-43 into inclusions. In
support of this, the overexpression of C-terminal TDP-43
fragments in various cell lines leads to the aggregation of
TDP-43 into insoluble cytoplasmic inclusions (Winton et al.
2008;I g a ze ta l .2009; Nonaka et al. 2009; Zhang et al.
2009). Much remains unknown regarding the processes
responsible for the generation of TDP-43 cleavage products
and what role they play in the pathogenesis of disease.
Because C-terminal fragments lack a nuclear localization
signal, their shuttling between the cytoplasm and nucleus is
presumably impaired, and this would lead to a loss of TDP-
43 function. Additionally, the increased presence of TDP-43
in the cytosol, either in a soluble or insoluble form, may
cause a toxic gain of function. Since animals can be killed at
differenttime-points duringdisease,theyprovide anideal tool
withwhichtoexaminetheinvolvementofC-terminalTDP-43
fragments in TDP-43 toxicity. For example, in Prp-TDP-
43A315T mice, C-terminal TDP-43 fragments of approxi-
mately ∼25 and ∼35 kDa are observed in the brain and spinal
cord at an early stage, prior to the onset of gait abnormalities
and significant brain pathology (Wegorzewska et al. 2009). It
is noteworthy that the TDP-43 fragments observed in these
Prp-TDP-43A315T mice are mostly present in a soluble form,
consistent with the lack of insoluble TDP-43 inclusions. By
way of subcellular fractionation studies, Stallings and
colleagues also found a clear correlation between disease
progression and an increase in the presence of cytoplasmic
full-length TDP-43, as well as TDP-43 fragments, in Prp-
TDP-43A315T mice. Wils et al. (2010)o b s e r v e da∼25 kDa
TDP-43 fragment only in the nuclear fraction of brains from
492 J Mol Neurosci (2011) 45:486–499Thy1-TDP-43 mice and found that levels of this fragment
increase with disease severity, whereas levels of ∼35 kDa
TDP-43 fragments, present in both the nucleus and cyto-
plasm, decrease with increasing disease severity (Wils et al.
2010). While correlative, the findings from these studies
are consistent with the hypothesis that ∼25 kDa C-
terminal fragments play an important role in TDP-43-
mediated neurodegeneration. They suggest that TDP-43
fragments are toxic in and of themselves and not
necessarily because they assemble into inclusions.
Arguing against this hypothesis are findings from other
TDP-43 transgenic models that suggest TDP-43 frag-
ments are generated only after the first appearance of
symptoms. For example, Tsai and colleagues found that
the appearance of ∼25- and 35-kDa TDP-43 fragments
in the urea-soluble fractions of brain extracts from
CaMKII-mTDP-43 mice coincides with motor deficits,
but occurs only after signs of cognitive impairment.
Likewise, Zhou et al. (2010) report that TDP-43 frag-
ments are present only at end-stage of disease, suggesting
that the formation of such fragments is a consequence,
rather than a cause, of neurodegeneration in TDP-43
transgenic rats. Finally, there exist TDP-43 transgenic
models with signs of neurodegeneration and/or premature
death in which TDP-43 fragments are not generated (Shan
et al. 2010;I g a ze ta l .2011), indicating that, at least in
these models, TDP-43 cleavage products are not respon-
sible for TDP-43-mediated toxicity. Again, however, this
does not rule out the potentially harmful consequence of
TDP-43 fragments were they to be formed.
Nuclear TDP-43 Inclusions and Altered Distribution
of Gemini of Coiled Bodies
In addition to cytoplasmic inclusions, TDP-43-positive
inclusions can take the form of dystrophic neurites and
intranuclear inclusions in ALS-TDP and FTLD-TDP
(Gendron et al. 2010). TDP-43-immunopositive nuclear
inclusions are also observed in some TDP-43 transgenic
models (Shan et al. 2010; Stallings et al. 2010; Wils et al.
2010; Xu et al. 2010). Of note, the Thy1-TDP-43 mice
generated by Shan and colleagues develop TDP-43-positive
nuclear aggregates that also contain SC35, a marker of non-
snRNP (small nuclear ribonucleoprotein), and the fused in
sarcoma (FUS) protein, two proteins involved in RNA
metabolism. Like TDP-43, FUS is an RNA-binding protein
that forms aggregates in certain cases of ALS and FTLD. It
has been shown to co-localize with TDP-43 in familial and
sporadic ALS (Deng et al. 2010), although other groups
report that TDP-43 and FUS pathology in ALS and FTLD
are mutually exclusive (Kwiatkowski et al. 2009; Neumann
et al. 2009; Vance et al. 2009; Hewitt et al. 2010; Seelaar et
al. 2010).
In addition to TDP-43-containing nuclear inclusions,
Thy1-TDP-43 mice have an increased number of Gemini of
coiled bodies in the nucleus of motor neurons, whereas
GEMs are absent altogether in mice in which TDP-43
expression is prevented (Shan et al. 2010). GEMs, small
punctate nuclear structures, are enriched with survival
motor neuron (SMN) protein and play a role in small
nuclear ribonucleoprotein maturation and pre-RNA splic-
ing. Using SMN minigenes, TDP-43 was previously shown
to enhance exon 7 inclusion and stability of SMN2 in
cultured cells (Bose et al. 2008). This function of TDP-43
may underlie the increase in GEMs observed in Thy1-TDP-
43 mice. While the role of increased GEMs in TDP-43-
induced toxicity remains to be determined, these findings
suggest that TDP-43 overexpression impacts pathways that
control RNA metabolism.
Loss of Nuclear TDP-43
In ALS-TDP and FTLD-TDP, a loss of nuclear TDP-43
staining is commonly observed in affected spinal cord and/
or brain neurons (Neumann et al. 2006). Although
exogenous TDP-43 in TDP-43 transgenic rodents is
primarily nuclear, in some models, a loss of nuclear TDP-
43 in selectively vulnerable neurons is observed prior to
obvious signs of degeneration (Wegorzewska et al. 2009;
Tsai et al. 2010;W i l se ta l .2010;I g a ze ta l .2011). To mimic
the nuclear clearance of TDP-43, Igaz and colleagues
generated transgenic mice that inducibly overexpress,
within the forebrain, human TDP-43 with a mutated nuclear
localization signal (iTDP-43ΔNLS) using the CaMKII
tetracycline-off inducible system (Igaz et al. 2011). This
paradigm was based on their earlier findings that expression
of TDP-43ΔNLS in cultured cells accumulates into
cytoplasmic aggregates and also sequesters endogenous
nuclear TDP-43 (Winton et al. 2008). iTDP-43ΔNLS mice
develop neuron loss in the cortex and hippocampus, as well
as degeneration of the corticospinal tract (Igaz et al. 2011).
However, unlike cultured cells expressing TDP-43ΔNLS,
few ubiquitin- and phosphorylated-TDP-43-immunoposi-
tive cytoplasmic aggregates are present in iTDP-43ΔNLS
mice. What is more, TDP-43 inclusions do not correlate
with neurotoxicity in this model. Nonetheless, a dramatic
loss of endogenous nuclear mTDP-43 is observed in iTDP-
43ΔNLS mice, as well as in mice that inducibly express
full-length TDP-43, and this phenotype does correlate with
the rate and extent of neurodegeneration (Igaz et al. 2011).
Double-label immunofluorescence studies using antibodies
specific to either mouse or human TDP-43 revealed that
neurons expressing exogenous human TDP-43 exhibit
decreased staining for endogenous mTDP-43. This decrease
in mTDP-43 does not result from its sequestration into
cytoplasmic inclusions (Igaz et al. 2011) but is most likely
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protein expression. Xu and colleagues have shown that
mTDP-43 mRNA levels decrease upon expression of
human TDP-43 in PrP-TDP-43WT mice, indicating that a
compensatory mechanism exists to tightly control levels of
mTDP-43 (Xu et al. 2010). Indeed, it has since been shown
that TDP-43 auto-regulates its mRNA levels through a
negative feedback loop; TDP-43 binds to 3′UTR sequences
in its own mRNA and this promotes RNA instability (Ayala
et al. 2011).
Since loss of mTDP-43 correlates with neurodegenera-
tion in iTDP-43ΔNLS and iTDP-43 mice (Igaz et al. 2011),
the authors speculate that perturbations of endogenous
nuclear mTDP-43 results in loss of normal TDP-43
function, culminating in the degeneration of selectively
vulnerable neurons. Certainly, there is a great deal of
evidence supporting that mTDP-43 function is critical for
the survival of mice. For example, knock-down of mTDP-
43 expression in mice causes motor deficits (Kraemer et al.
2010), and knock-out of mTDP-43 results in embryonic
lethality (Chiang et al. 2010; Kraemer et al. 2010; Sephton
et al. 2010;W ue ta l .2010). Furthermore, even if
embryonic lethality is overcome by knocking-out mTDP-
43 expression only after the birth of mice, rapid death still
ensues (Chiang et al. 2010). It remains possible, however,
that loss of endogenous mTDP-43 is not the contributing
factor leading to neurodegeneration in iTDP-43ΔNLS and
iTDP-43 mice. TDP-43 transgenic mice overexpressing
mTDP-43 display similar neurodegeneration and share
many characteristics as mice overexpression human TDP-
43, even though they maintain high levels of nuclear
mTDP-43 (Tsai et al. 2010). Furthermore, mouse and
human TDP-43 are highly homologous, especially within
the RNA recognition motifs (Wang et al. 2004). Given this,
the question arises as to why loss of endogenous nuclear
mTDP-43 in iTDP-43 mice should be detrimental to
neurons when human TDP-43 levels within the nucleus
remain elevated. Of course, it must be mentioned that
mTDP-43 may modulate specific and vital RNA targets that
cannot be regulated by human TDP-43. Moreover, multiple
TDP-43 isoforms are expressed in mice, and these may
have unique functions that cannot be compensated for by
full-length human TDP-43 (Wang et al. 2002; Wang et al.
2004).
With regards to iTDP-43ΔNLS mice, neurodegeneration
may be caused, not only by nuclear mTDP-43 depletion,
but also by enhanced hTDP-43 expression within the
cytoplasm. In rat primary cortical cultures that overexpress
EGFP-TDP-43A315T, neuronal survival is unaffected by the
total amount of exogenous TDP-43 in the nucleus, yet the
amount of cytoplasmic TDP-43 is a strong predictor of
neuronal death (Barmada et al. 2010). Importantly, prevent-
ing the nuclear export of EGFP-TDP-43A315T by mutating
its nuclear export signal significantly blunts the toxicity
associated with EGFP-TDP-43A315T expression, confirming
that it is the cytoplasmic mislocalization of EGFP-TDP-
43A315T that induces neuronal toxicity in rat primary
neurons (Barmada et al. 2010). Whether a similar mecha-
nism is responsible for toxicity in vivo has yet to be
determined, nor is it definitely known whether it is the loss
of endogenous mTDP-43, per se, that induces toxicity, or
rather the dysregulation of TDP-43 expression in general.
Mitochondrial Abnormalities
Among the notable features characterized in rodent TDP-43
transgenic models, Xu and colleagues were first to report
that TDP-43 overexpression in vivo has a profound effect
on mitochondria. They found that PrP-TDP-43WT mice
develop cytoplasmic eosinophilic aggregates in spinal
motor neurons that sometimes displace the nucleus.
Ultrastructural analysis revealed that these eosinophilic
aggregates are composed of clusters of abnormal mitochon-
dria, many of which have features suggestive of degener-
ation, such as decreased cristae and vacuoles within the
mitochondrial matrix (Xu et al. 2010). The clustering of
mitochondria is also present in Thy1-TDP-43 mice gener-
ated by Shan and colleagues, as well as in PrP-TDP-
43A315T mice developed by the Baloh group, indicating that
this phenotype is not unique to one model (Shan et al.
2010; Wegorzewska and Baloh 2011).
How TDP-43 overexpression in mice causes mitochon-
dria to cluster, and what effect it may have on mitochondrial
function, is not yet known. Given the primarily nuclear
localization of exogenous TDP-43 in these transgenic
models, it is likely that aberrations in nuclear TDP-43
function underlie the mitochondrial abnormalities, as
opposed to a direct association of TDP-43 with mitochon-
dria. Since changes in fission or fusion have previously
been shown to cause abnormal perinuclear clustering of
mitochondria (Baloh et al. 2007; Huang et al. 2007; Wang
et al. 2008b), one potential cause may be that TDP-43
overexpression leads to the misregulation of transcripts that
encode proteins which modulate mitochondria fission or
fusion. Indeed, the expression of key proteins in the
regulation of mitochondrial fission and fusion were found
to be abnormally expressed or regulated in PrP-TDP-43WT
mice (Xu et al. 2010). TDP-43-mediated mitochondrial
clustering may alternatively result from aberrant splicing or
transcription of crucial mediators of axonal transport.
Altered mitochondrial trafficking in association with pro-
teins linked to neurodegenerative disease is not without
precedent (Vives-Bauza et al. 2010). The presence of
axonal degeneration in spinal cord neurons, together with
perinuclear clusters of mitochondria in PrP-TDP-43WT
mice, does suggest that axonal transport deficits may cause
494 J Mol Neurosci (2011) 45:486–499the abnormal distribution of mitochondria. To directly
evaluate the distribution of mitochondria in different
compartments of motor neurons, Shan and colleagues
crossed Thy1-TDP-43 mice with Thy1-mitoCFP mice, in
which a subpopulation of mitochondria are fluorescently
labeled with CFP in neurons. In Thy1-mitoCFP mice, CFP-
labeled mitochondria are evenly distributed in the cell body
of motor neurons and are also present in neuronal
processes. In contrast, mitochondria cluster into inclusions
within cell bodies of motor neurons in Thy1-mitoCFP/
TDP-43 mice (Shan et al. 2010). The sparse distribution of
mitochondria in neuronal processes suggests that trafficking
of mitochondria is impaired. Consistent with this specula-
tion, there is an obvious reduction of mitochondria at nerve
terminals of neuromuscular junctions in Thy1-mitoCFP/
TDP-43 mice. Moreover, Kif3a and KAP3, proteins
associated with the motor protein kinesin, are localized
within the mitochondrial clusters of Thy1-TDP-43 mice
(Shan et al. 2010).
Taken together, these results suggest that aberrations in
mitochondrial dynamics and/or trafficking may play a role in
TDP-43-mediated toxicity. Of note, the expression of TDP-43
in NSC-34 cells induces mitochondrial dysfunction and
oxidative stress in the absence of TDP-43 inclusion formation
(Duanetal.2010). Additionally, the expression of TDP-43 in
yeast, which leads to the formation of perimitochondrial
TDP-43 aggregates, causes mitochondrial-dependent oxida-
tive stress and cytotoxicity (Braun et al. 2011). It is
especially noteworthy that abnormal mitochondria accumu-
late in presynaptic axosomatic terminals of motor neurons in
ALS (Sasaki and Iwata 1999) and that cytoplasmic granules
in motor neurons contain mitochondria with TDP-43
immunoreactivity (Mori et al. 2008). Also of interest is
the observation that SOD1 is associated with aberrant
spinal motor neuron mitochondria in humans and
rodents with ALS due to SOD1 mutations and that
mitochondrial clusters are present in motor axons of
mutant SOD1 transgenic rats (Sotelo-Silveira et al.
2009). Together, these findings implicate mitochondrial
abnormalities in TDP-43-induced toxicity and provide a
potential convergence between TDP-43 and SOD1 in the
pathogenesis of ALS.
Conclusions
Although many questions remain regarding the mechanisms
underlying TDP-43-mediated neurodegeneration, the find-
ings emerging from the above-mentioned TDP-43 trans-
genic animal models bring to light a number of interesting
observations. For instance, TDP-43-induced toxicity is
dependent on the level of transgene expression, with
intermediate expression of TDP-43 producing an attenuated
phenotype, if any, compared with animals expressing higher
TDP-43 levels (Stallings et al. 2010; Wils et al. 2010;X ue t
al. 2010; Igaz et al. 2011). Of particular interest, compared
with controls, FTLD-TDP brain samples show substantially
higher total amounts of TDP-43, including high and low
molecular weight TDP-43 species (Guo et al. 2011).
Additionally, while no copy number variation of the
TARDBP locus have been identified in ALS-TDP or
FTLD-TDP (Gijselinck et al. 2009), perhaps because of
the toxicity associated with heightened TDP-43 expression,
sequencing analyses has identified a variant in the 3′-UTR
TARDBP in a FTLD-TDP patient that increases TDP-43
mRNA levels (Gitcho et al. 2009).
The comparison of TDP-43 transgenic models indicates
that both wild-type and mutant TDP-43 are neurotoxic upon
overexpression.However,thethresholdofTDP-43expression
required to induce toxicity appears to be lower for mutant
TDP-43thanforwild-type TDP-43.ThatmutantTDP-43may
be more toxic than wild-type TDP-43 in rodents is consistent
with some studies conducted in other model organisms,
including yeast (Johnson et al. 2009), chicken embryos
(Sreedharan et al. 2008), Drosophila melanogaster (Guo et
al. 2011), and mammalian cells (Guo et al. 2011).
Even though mutations in TARDBP have been identified
in a relatively small proportion of ALS patients, under-
standing how these mutations confer toxicity is expected to
provide insight on the role of TDP-43 in neurodegenera-
tion. Certain mutations accelerate the aggregation of TDP-
43 in vitro and in yeast (Johnson et al. 2009), as well as in
cultured cells (Nonaka et al. 2009; Liu-Yesucevitz et al.
2010; Guo et al. 2011). Mutations in TDP-43 also alter
TDP-43 stress granule formation, leading to increased
TDP-43 inclusion formation in response to stressful stimuli
(Liu-Yesucevitz et al. 2010; Dewey et al. 2011). Further-
more, mutant TDP-43 is reportedly more prone to misloc-
alize to the cytoplasm of primary neurons, where it induces
a toxic gain-of-function and cell death (Barmada et al.
2010). Additionally, some mutations are thought to increase
the propensity of TDP-43 to become cleaved into C-
terminal fragments (Kabashi et al. 2008; Rutherford et al.
2008; Sreedharan et al. 2008; Yokoseki et al. 2008; Corrado
et al. 2009) and to produce higher amounts of protease-
resistant fragments of 10–11 and 24–25 kDa (Guo et al.
2011). With regards to TDP-43 transgenic animals, few
TDP-43 inclusions are observed, indicating that TDP-43
aggregation is not the initiating neurotoxic factor in these
models. However, TDP-43 mislocalization and fragmenta-
tion do arise in various models (Table 1), suggesting that
these abnormalities may play a role, at least in part, in TDP-
43-mediated neurodegeneration.
Not only may cytosolic TDP-43 species contribute
disease pathogenesis by a toxic gain of function, but they
may also lead to the dysregulation of normal TDP-43
J Mol Neurosci (2011) 45:486–499 495function. Of note, altered RNA expression and splicing are
likely contributors to TDP-43 toxicity in rodent TDP-43
transgenic models. Using a transcriptome-wide differential
RNA expression (RNA-Seq) approach, Shan and col-
leagues identified 313 genes with changes in splicing
pattern and 2,017 genes that are differently expressed in
spinal cord of Thy1-TDP-43 mice compared with non-
transgenic controls. Similarly, more than 4,700 genes were
differently expressed between iTDP-43ΔNLS and non-
transgenic mice, as assessed by microarray analysis (Igaz et
al. 2011). Based on biological pathway analysis, the
“macromolecular complex organization” pathway was
among the top dysregulated pathways in iTDP-
43ΔNLS mice, with genes involved in chromatin
assembly accounting for a significant enrichment in this
category (Igaz et al. 2011). These two studies highlight
that TDP-43 overexpression, and the consequences there-
of, influence the regulation of a vast number of RNA
targets. Indeed, several groups have undertaken the
daunting task of identifying TDP-43 RNA targets in
cultured cells, mouse brain, and human brain from FTLD
or ALS patients (Polymenidou et al. 2011; Tollervey et al.
2011; Xiao et al. 2011). These studies emphasize that
TDP-43 interacts with a diverse spectrum of RNA targets
with important functions in the brain. As such, a greater
understanding of the role played by TDP-43 in regulating
the splicing and expression of RNA is crucial. This
information will help decipher how the characteristic traits
of ALS-TDP and FTLD-TDP, such as TDP-43 mislocal-
ization, truncation, phosphorylation, and aggregation
influence TDP-43 RNA metabolism. TDP-43 transgenic
rodents, which recapitulate many of these features, should
prove valuable in this endeavor.
Overall, the novel transgenic animals described herein,
combined with other in vivo and in vitro models, provide
much needed tools with which to answer the many
questions regarding TDP-43 function and dysfunction. As
the gaps in our knowledge continue to narrow, the
likelihood of developing successful therapeutic strategies
for the treatment of ALS-TDP and FTLD-TDP will greatly
improve.
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